$23.6M
CEO Total Comp · FY2025
Christopher Viehbacher · 67th vs. peers
93.87%
Say-on-Pay · FY2025
Most recent annual vote
1.19×
Realizable / Granted
$28.2M realizable††
not stated
STI Payout · FY2025
Payout basis not disclosed
Thesis
Compensation positioning, governance posture, and pay-for-performance screens are summarized across the following pages.
Calibration anchors as of August 12, 2026 (stock price $203.89; market cap $30.1B).
Priority Actions
P1Governance
Say-on-Pay support of 67.91% ranks last of 15 peers — below MRNA (65.11%) and INCY (83.86%), against a 93.82% median. This is the third sub-70% result in five years (69.48% FY2022, 52.08% FY2021).
P2Governance
Biogen's philosophy ties pay to long-term stockholder value, yet Viehbacher's $23.6M sits at P67 — above BMRN ($21.9M), below AMGN ($24.7M) — against a -23.91% 3-year TSR.
P3Governance
The two-metric PSU structure (Relative TSR, Adjusted EPS CAGR) is thinner than BMRN's four metrics, putting Biogen in the minority on metric diversity even as its 60% PSU / 40% RSU split matches MRK.
Since the Last Disclosure
Activity since the last disclosure — $21.6M of equity awarded across 10 awards to 10 people since Jan 1, 2026. None of it reaches a compensation table until the FY2026 disclosure is published.
Shareholder vote in the current window — 93.87% support on Jun 9, 2026, with 10 awards granted before the vote and 0 after it.